Balyasny Asset Management
MNPR icon

Balyasny Asset Management’s Monopar Therapeutics MNPR Stock Holding History

Balyasny Asset Management’s Portfolio MNPR Stock Details MNPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.48M Buy
136,443
+104,536
+328% +$6.31M 0.01% 1167
2025
Q4 		$2.08M Buy
+31,907
New +$2.61M ﹤0.01% 1837
2025
Q2 		– Sell
-6,141
Closed -$224K – 3151
2025
Q1 		$224K Buy
+6,141
New +$221K ﹤0.01% 2550

Other funds holding MNPR

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Balyasny Asset Management's MNPR Position: Q1 2026 in Review

Balyasny Asset Management increased its Monopar Therapeutics (MNPR) stake by 328% in Q1 2026, buying an estimated $6.31M and bringing the position to 136,443 shares worth $7.48M. The position accounts for 0.01% of the portfolio, ranked #1167.

Balyasny Asset Management first reported a position in MNPR in Q1 2025 and has held it in 3 quarters since. 82 funds tracked by Wall St. Rank hold MNPR as of Q1 2026.

  • Balyasny Asset Management held 136,443 shares of Monopar Therapeutics worth $7.48M as of Q1 2026.
  • Balyasny Asset Management bought 104,536 Monopar Therapeutics shares in Q1 2026, an estimated $6.31M.
  • Monopar Therapeutics made up 0.01% of Balyasny Asset Management's portfolio in Q1 2026, its #1167 holding.
  • Balyasny Asset Management first reported a position in Monopar Therapeutics in Q1 2025 and has held it in 3 quarters since.
  • 82 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.